Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation

NCT05226455 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT05226455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05226455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 23, 2022
Completion date
September 1, 2027
Enrollment
55 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds